Abstract:Cancer specific extracellular vesicles (EVs) are of significant clinical relevance, for instance programmed death ligand-1 (PD-L1) expressing EVs (PD-L1@EVs) have been shown to be ideal biomarker for non-invasive diagnosis of cancer and can predate the response of cancer patients to anti-PD-1/PD-L-1 immunotherapy. The development of sensitive and straightforward methods for detecting PD-L1@EVs can be a vital tool for non-invasive diagnosis of cancer. Most of the contemporary methods for EVs detection have limitations such as involvement of long and EV's loss prone isolation methods prior to detection or they have employed expensive antibodies and instruments to accomplish detection. Therefore, we designed an ultracentrifugation-free and antibody-free sensing assay for PD-L1@EV by integrating Titanium oxide (TiO2) coated magnetic beads (Fe3O4@TiO2) rapid capturing of EVs from undiluted serum with aptamers specificity and chemiluminescence (CL) sensitivity. To accomplish this we used Fe3O4@TiO2 beads to rapidly capture EVs from the undiluted patient serum and added biotin labelled PD-L1 aptamer to specifically recognize PD-L1@EVs. Later, added streptavidin-modified Alkaline phosphates (ALP) taking advantage of biotin-streptavidin strong binding. Addition of CDP-star, a chemiluminescent substrate of ALP, initiates the chemiluminiscense that was recorded using spectrophotometer. The sensing assay showed high sensitivity with limit of detection (LOD) as low as 2.584×105 EVs/mL and a wider linear correlation of CL intensity (a.u.) with the concentration of PD-L1@EVs from 105 to 108 EVs/mL. To examine the clinical utility of sensing assay we used undiluted serum samples from lung cancer patients and healthy individuals and successfully discern between healthy individuals and lung cancer patients. We are optimistic that the sensing assay can ameliorate our ability to be able to diagnose lung cancer non-invasively and can be helpful to predate the patient's response to anti-PD-1/PD-L1 immunotherapy.

Reliable Detection of Extracellular PD-L1 by DNA Computation-Mediated Microfluidics

Selective Enrichment and Detection of PD-L1 Positive Extracellular Vesicles Derived from Human Plasma and Patient Derived Tumor Cells

Comprehensive Detection of PD-L1 Protein and mRNA in Tumor Cells and Extracellular Vesicles through a Real-Time qPCR Assay

Single Extracellular Vesicle Analysis Using Droplet Microfluidics.

Localized Imaging of Programmed Death-Ligand 1 on Individual Tumor-Derived Extracellular Vesicles for Prediction of Immunotherapy Response

Rapid Enrichment and Sensitive Detection of Extracellular Vesicles Through Measuring the Phospholipids and Transmembrane Protein in a Microfluidic Chip.

A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1

Target proteins-regulated DNA nanomachine-electroactive substance complexes enable separation-free electrochemical detection of clinical exosome

Programmable DNA-Fueled Electrochemical Analysis of Lung Cancer Exosomes

A magneto-activated nanoscale cytometry platform for molecular profiling of small extracellular vesicles

Paper-based lipid bilayer magnetic interface for ultrasensitive assay of tumor-derived extracellular vesicles PD-L1

Predictive Analysis in Oral Cancer Immunotherapy: Profiling Dual PD-L1-Positive Extracellular Vesicle Subtypes with Step-Wedge Microfluidic Chips

High-resolution spiral microfluidic channel integrated electrochemical device for isolation and detection of extracellular vesicles without lipoprotein contamination

Double Digital Assay for Single Extracellular Vesicle and Single Molecule Detection

Integrated microfluidic system for isolating exosome and analyzing protein marker PD-L1

Rapid Capturing and Chemiluminescent Sensing of Programmed Death Ligand-1 Expressing Extracellular Vesicles

A PLA-mediated transistor biosensor enables specific identification of tumor-derived exosomal PD-L1

Simultaneous detection of membrane protein and mRNA at single extracellular vesicle level by droplet microfluidics for cancer diagnosis

PD-L1 Detection on Circulating Tumor-Derived Extracellular Vesicles (T-Evs) from Patients with Lung Cancer.

Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks

An Electrochemical Biosensor for PD-L1 Positive Exosomes Based on Ultra-Thin Two-Dimensional Covalent Organic Framework Nanosheets Coupled with CRISPR-Cas12a Mediated Signal Amplification